2nd Quarter - Report

AMGEN, INC. for AMGEN INC

Firm
Client
Income
—
Expenses
$1,950,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Research and experimentation tax incentives and international tax issues, including: Administrations FY 2014 corporate tax proposals, Tax Reform, including House Ways and Means and Senate Finance Committee Discussion Drafts HR 4438 American Research and Competitiveness ActHR 4464 Permanent CFC-Look-Through Act S.2260 Expiring Provisions Improvement, Reform and Efficiency (Expire) Act

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
L NICOLE CURRIE —
NANCY ELLEN MCCARTHY —
WILLIAM O'BRIEN —
HELEN RHEE —

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; Treasury, Dept of; Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 2260 (113th), H.R. 4438 (113th)

Copyright/Patent/Trademark CPT

H.R. 3309 The Innovation Act of 2013 (heightened pleading standards, discovery stay) S. 1720, The Patent Transparency and Improvements Act (demand letters, customer stay) S. 1013, The Patent Abuse Reduction Act (heightened pleading standards, discovery stay) S. 1612, The Patent Litigation Integrity Act (bonding)Trans-Pacific Partnership (12 years data exclusivity) S. 866, The Patient Quality Improvement Act (covered business method patents)

LobbyistCovered position, as disclosed
L NICOLE CURRIE —
WILLIAM O'BRIEN —
HELEN RHEE —

Contacted: Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Treasury, Dept of; U.S. Trade Representative (USTR)

Bills named: H.R. 3309 (113th), S. 1720 (113th), S. 866 (113th), S. 1013 (113th), S. 1612 (113th)

Health Issues HCR

Biosimilars, no specific bill Health Resources and Services Administration (HRSA) policy regarding rebates on drugs used in the outpatient setting to help low-income/uninsured populations (340B), no specific bill FDA Reform, no specific bill

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
L NICOLE CURRIE —
RUTH HOFFMAN —
JESSE KERNS —
REBECCA MANDELL —
HOWARD MOON —
WILLIAM O'BRIEN —
GREGORY PORTNER —
HELEN RHEE —

Contacted: SENATE; Treasury, Dept of; Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Medicare/Medicaid MMM

End Stage Renal Disease and issues related to dialysis Medicare Part B drug reimbursement issues (Average Sales Price) H.R. 4814 Chronic Kidney Disease Improvement in Research and Treatment Act (End Stage Renal Disease)

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
L NICOLE CURRIE —
RUTH HOFFMAN —
JESSE KERNS —
REBECCA MANDELL —
HOWARD MOON —
WILLIAM O'BRIEN —
GREGORY PORTNER —
HELEN RHEE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Treasury, Dept of; Executive Office of the President (EOP); U.S. Trade Representative (USTR)

Bills named: H.R. 4814 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.